IceCure Medical Ltd. Announces Positive THERMAC Trial Results for ProSense® Cryoablation in Breast Cancer, Achieving High Patient Satisfaction and Complete Ablation Rates
I'm PortAI, I can summarize articles.
IceCure Medical Ltd. announced positive results from the THERMAC Trial for its ProSense® cryoablation system in early-stage breast cancer. The trial, conducted in the Netherlands, showed ProSense® achieved the highest complete ablation rates and 95% patient satisfaction regarding cosmetic outcomes. Findings were published in the European Journal of Surgical Oncology and Radiology, indicating ProSense® as a preferred technique for future comparisons with surgery in phase III trials. The results were also presented at major medical conferences.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments